Riskpilot← Back to searchSign inGet full accessNYKODE THERAPEUTICS ASA
ASAActiveOrg 990646066Gaustadalleen 21, 0349 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 200746 employeeswww.nykode.com
Revenue 2024
NOK 9,2M
-31% vs 2023
EBITDA margin
-477.3%
+20% vs 2023
Equity ratio
89.8%
Financial strength
Net profit 2024
NOK -38,5M
-15% vs 2023
| Revenue | NOK 9,2M | -31% |
| EBITDA | NOK -43,7M | +20% |
| Net profit | NOK -38,5M | -15% |
| Total assets | NOK 156,1M | -26% |
| Equity | NOK 140,1M | -20% |
| Employees | 46 | — |
Legal name
NYKODE THERAPEUTICS ASA
Org number
990646066
Legal form
Allmennaksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13. januar 2007
Share capital
NOK 3 265 464
Employees
46 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Utvikling av biomedisinske produkter og tjenester. Formålet kan fremmes ved deltagelse i eller samarbeid med andre foretak i inn- og utland eller rådgivende virksomhet.
Address
Gaustadalleen 21, 0349 Oslo
Phone
+4722958193
Email
info@vaccibody.com
Website
www.nykode.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 215 695 | 35 766 | 9 029 | 13 362 | 9 158 |
| Staff expenses | −0 | −14 459 | −11 771 | −18 331 | −19 741 |
| EBITDA | 178 568 | −9 205 | −50 482 | −54 533 | −43 709 |
| Depreciation & amort. | −303 | −711 | −1 666 | −1 947 | −2 039 |
| EBIT | 178 265 | −9 916 | −52 148 | −56 480 | −45 748 |
| Net financials | 2 639 | −412 | 2 148 | 14 051 | 547 |
| Profit before tax | 180 904 | −10 328 | −50 000 | −42 429 | −45 201 |
| Tax | −0 | −1 731 | −8 320 | −9 037 | −6 722 |
| Net profit | 149 774 | −8 597 | −41 680 | −33 392 | −38 479 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 230 028 | 265 755 | 223 706 | 210 353 | 156 082 |
| Equity | 178 850 | 194 866 | 158 826 | 174 832 | 140 142 |
| Long-term debt | 37 997 | 35 219 | 25 444 | 15 664 | 7 857 |
| Short-term debt | 13 181 | 30 754 | 39 406 | 19 855 | 8 083 |
| Total debt | 51 178 | 65 973 | 64 850 | 35 519 | 15 940 |
EBITDA margin
-477.3%
This company
15.8%
Market median
-3121% vs market
20202024
Equity ratio
89.8%
This company
38.2%
Market median
+135% vs market
20202024
Return on equity
-27.5%
This company
18.4%
Market median
-249% vs market
20202024
Net profit margin
-420.2%
This company
8.1%
Market median
-5288% vs market
20202024
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20202024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MT Chief Executive Officer | Chief Executive Officer | 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Chairman | 2025 | |
| Board of Directors | 2022 | |
| Board of Directors | 2026 | |
| Board of Directors | 2025 | |
| Chairman | 2026 | |
| Former (11) | ||
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2024 – 2025 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2021 – 2021 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2023 – 2025 | |
| Chairman | 2022 – 2025 | |
| Chairman | 2022 – 2022 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2022 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 9.24% | 9.24% | 2024 | |
| Company | 7.96% | 7.96% | 2024 | |
| Company | 5.42% | 5.42% | 2024 | |
State Street Bank And Trust Comp | Company | 4.66% | 4.66% | 2024 |
| Company | 3.98% | 3.98% | 2024 | |
| Company | 3.85% | 3.85% | 2024 | |
| Company | 3.23% | 3.23% | 2024 | |
| Company | 3.16% | 3.16% | 2024 | |
| Company | 2.29% | 2.29% | 2023 | |
| Company | 2% | 2% | 2024 | |
| Company | 1.38% | 1.38% | 2024 | |
| Company | 1.37% | 1.37% | 2024 | |
Clearstream Banking S.A. | Company | 1.15% | 1.15% | 2024 |
| Company | 1.07% | 1.07% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Lucy As
NYKODE THERAPEUTICS ASA Board members of NYKODE THERAPEUTICS ASA also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Michael Thyrring Engsig | Chief Executive Officer | 0 companies |
| Jan Haudemann-Andersen | Board of Directors | 0 companies |
| Susanne Stuffers | Chairman | 0 companies |
| Lars Lund-Roland | Board of Directors | 0 companies |
| Christian Åbyholm | Board of Directors | 0 companies |
| Einar Jørgen Greve | Board of Directors | 0 companies |
| Anne Clem Whitaker | Board of Directors | 0 companies |
| Berno Robert Seizinger | Board of Directors | 0 companies |
| Bernd Robert Seizinger | Board of Directors | 0 companies |
| Harald Arnet | Board of Directors | 0 companies |
| John William Beadle | Board of Directors | 0 companies |
| Trygve Lauvdal | Board of Directors | 0 companies |
| Alf Gunnar Martin Nicklasson | Chairman | 0 companies |
| Anders Tuv | Chairman | 0 companies |
| Barbara Helene Hannelore Krebs-Pohl | Chairman | 0 companies |
| Elaine Sullivan | Board of Directors | 0 companies |
| Birgitte Volck | Board of Directors | 0 companies |